Journal of Neurology

, Volume 255, Supplement 6, pp 15–21

Immunomodulatory treatment strategies in multiple sclerosis

Authors

    • Dept. of NeurologyHeinrich-Heine University
  • Heinz Wiendl
    • Dept. of NeurologyJulius-Maximilians University
  • Verena I. Leussink
    • Dept. of NeurologyHeinrich-Heine University
  • Olaf Stüve
    • Neurology SectionVA North Texas Health Care System Medical Service
    • Dept. of Neurology and Dept. of ImmunologyUniversity of Texas Southwestern Medical Center at Dallas
Article

DOI: 10.1007/s00415-008-6004-z

Cite this article as:
Kieseier, B.C., Wiendl, H., Leussink, V.I. et al. J Neurol (2008) 255: 15. doi:10.1007/s00415-008-6004-z

Abstract

Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults. The mainstays in the immunomodulatory therapy of MS are currently interferon beta and glatiramer acetate, both of which have proven to be clinically and paraclinically effective. Current clinical evidence indicates that treatment should be initiated as early as possible. In this review we summarize available data from clinical studies on clinical efficacy of immunomodulatory drugs for treating patients with multiple sclerosis.

Key words

multiple sclerosisimmunomodulationinterferon betaglatiramer acetat
Download to read the full article text

Copyright information

© Steinkopff-Verlag 2008